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The serum and glucocorticoid kinase (SGK) is a family of serine/threonine kinases which includes 
three isoforms, SGK1, SGK2 and SGK3. SGK1 recently appeared as an essential and non-
redundant target in cancer therapy, being involved in the development and resistance of human 
tumours. Furthermore, SGK1 plays a critical role in metabolic syndrome. Nevertheless, only few 
SGK1 inhibitors have been reported in the literature to date [1]. 
In this context, we decided to virtually screen our library of pyrazolo[3,4-d]pyrimidines, originally 
synthesized to target the tyrosine kinases Src and Abl, in order to find potential SGK1 inhibitors. 
This in silico study led to the identification of a few promising compounds that have been tested on 
SGK1 and a small panel of kinases. Among these molecules, SI113 (Figure 1) shows an IC50 value 
of 600 nM on SGK1 and results quite selective for this kinase compared with AKT-1, Src and Abl 
[2]. SI113 possesses pro-apoptotic and anti-proliferative effects in different cancer cell lines, 
synergizing with radiotherapy in tumor killing [3,4]. Interestingly, SI113 inhibits tumour growth in 
hepatocarcinoma models in vitro and in vivo. Moreover, no side effects, e.g. weight loss, diarrhea, 
dermatitis, or signs of liver failure, appeared in SI113 treated mice [3]. 
Starting from these exciting results, we decided to start a hit-to-lead study aimed at discovering new 
SGK1 inhibitors endowed with a better activity than SI113 and a good pharmacokinetic profile. 
Here, we report an overview of the activity of the hit compound SI113 and an update on the work in 














NHR = aliphatic or aromatic amino groups
R1 = NHCH2CH2OH, N(CH2CH2OH)2,
        morpholine
X = H, halogen atoms
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Figure 1 - Structure of the hit compound SI113 and new generation of SGK1 inhibitors 1 
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